Disease-modifying drugs for Alzheimer disease: implications for people in Canada
Jennifer Watt, Wanrudee Isaranuwatchai, Linda Grossman, Sharon E. Straus
Abstract
KEY POINTS At least 250 000 people in Canada live with mild dementia, and 1.3 million live with mild cognitive impairment.[1][1]–[3][2] Alzheimer disease is implicated in 60%–70% of cases of dementia and 30%–77% of cases of mild cognitive impairment.[4][3],[5][4] There are no recommended
Topics & Concepts
DementiaDiseaseCognitive impairmentAlzheimer's diseaseMedicineCognitive declineCognitionGerontologyPsychiatryPathologyCholinesterase and Neurodegenerative DiseasesAlzheimer's disease research and treatmentsComputational Drug Discovery Methods